Scienture wins US patent for REZENOPY naloxone nasal spray, protection through 2041

Scienture Holdings, Inc.

Scienture Holdings, Inc.

SCNX

0.00
  • Scienture Holdings received a US patent covering REZENOPY naloxone HCl nasal spray 10 mg, effective May 12, 2026; expires Feb. 5, 2041.
  • Patent adds IP protection ahead of a planned mid-July US commercial launch of the 10 mg product, the highest FDA-approved naloxone dose per spray.
  • Exclusive US commercialization rights secured under a March 2025 agreement with Summit Biosciences, which will manufacture and supply the product.
  • IQVIA data show the US naloxone market at about USD 141 million in annual sales on 9,400,000 units as of January 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scienture Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606020805PRIMZONEFULLFEED9730239) on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.